ALT250110P16000
- 0.00
- 0.000.00%
Altimmune Newsroom
Jefferies Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $28
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)
Promising Prospects for Altimmune: Buy Rating Backed by Upcoming Data Readout and Strategic Expansion
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Stifel Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $18
Altimmune Price Target Announced at $18.00/Share by Stifel
Altimmune Analyst Ratings
Stifel Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $18
Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy's Buy Rating on Altimmune's Pemvidutide
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Institutional Owners May Consider Drastic Measures as Altimmune, Inc.'s (NASDAQ:ALT) Recent US$56m Drop Adds to Long-term Losses
Jim Cramer on Altimmune, Inc. (ALT): 'Healthcare Is So Out Of Fashion'
Most Shorted Stocks on Wall Street Heading Into 2025: BYND, KSS, GRPN, and More
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)
Altimmune Call Volume Above Normal and Directionally Bullish
Express News | Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket